To address this question, we interrogated the accessible chromatin at the individual cell level in gliomas with IDH mutation using single nucleus Assay for Transposase-Accessible Chromatin with high-throughput sequencing (snATAC-seq) on a subset of 5 patient samples. This evidence concerns the gene IDH2 and glioma.